Eva Feldman

Last updated
Feldman in 2022 Dr.Feldman Lab0057 CORRECT Square.jpg
Feldman in 2022

Eva Lucille Feldman is an American physician-scientist who is a leading authority on neurodegenerative disease. She serves as the Russell N. DeJong Professor of Neurology at the University of Michigan, as well as Director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also named the James W. Albers Distinguished University Professor of Neurology.

Contents

Feldman has made contributions to biomedical research and clinical care in many areas of neurodegenerative disease.  Her primary focus has been on amyotrophic lateral sclerosis (ALS), Alzheimer's disease, cognitive decline, and the neurologic complications of diabetes and obesity, as well as how environmental toxins affect the nervous system. She also has conducted pioneering research on developing stem cell therapies to treat these diseases.

She has been annually listed in Best Doctors in America and is a member of the Association of American Physicians and National Academy of Medicine. She is on the National Academy of Medicine (governing and oversight) Council and a Fellow of the American Association for the Advancement of Science. Feldman has authored over 500 articles, 70 book chapters (Google Scholar h-index = 109) with >45,000 citations. She has been continuously NIH funded since 1989.

Early life and education

Eva Feldman grew up in Indiana and completed her undergraduate degree in biology at Earlham College with honors, followed by an M.S. in zoology at the University Notre Dame.  Feldman then went on to receive both her M.D. and Ph.D. at the University of Michigan as a Rackham Scholar.  She completed her Neurology residency at Johns Hopkins, where she served as Chief Resident and received The Johns Hopkins Award for Medical Teaching and Excellence, the first neurologist to receive this award at Hopkins. Dr. Feldman then returned to the University of Michigan to complete a neuromuscular disorders fellowship, with longtime mentor Dr. James Albers, and her career has since progressed to her current role as the Russell N. DeJong Professor of Neurology and Director of both the NeuroNetwork for Emerging Therapies and ALS Center of Excellence.

Career

In 1988, Feldman became an assistant professor and opened her basic science laboratory in the Department of Neurology at Michigan Medicine, serving as member of the Neuroscience Program and Michigan Diabetes Research and Training Center. In 1994, she became an associate professor, and in 1998 she joined the faculty of the Cellular and Molecular Biology Program.

In 2000, Feldman became director of the Juvenile Diabetes Research Foundation Center for the Study of Complications in Diabetes (until 2010), Director of the ALS Center of Excellence at Michigan Medicine, and a fully endowed professor, the Russell N. DeJong Professor of Neurology. In 2005, she was named the Director of Michigan Medicine’s Neuropathy Center. She was appointed the inaugural Director of the A. Alfred Taubman Medical Research Institute in 2007, after U-M received a multimillion-dollar gift from A. Alfred Taubman for its creation.

Feldman is the author of more than 500 articles, 71 book chapters, and four books. Her research has been funded continually by the National Institutes of Health (NIH) for over 30 years, and she currently is the principal investigator or co-Investigator of grants funded by the NIH, including the NIH Director’s Transformative Research Award in 2021, as well as grants from the Centers for Disease Control and Prevention’s Agency for Toxic Substances and Disease Registry, the Juvenile Diabetes Research Foundation and private foundations. Feldman also leads multiple clinical trials focused on understanding and treating neurological disorders, with an emphasis on ALS and neuropathy.

Feldman served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. At that time, she was only the third woman elected as ANA President in 130 years. She was the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. She is also the only U-M alumnus to receive both Early and Distinguished Career Achievement Awards from the U-M Medical Alumni Society. This year, she was also given the University of Michigan's most prestigious honor, a Distinguished University Professorship, which was named after her longtime mentor James Albers, M.D., Ph.D. Among her many honors, Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. In 2023, she was appointed to the National Academy of Medicine (governing and oversight) Council.  Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology , Nature Reviews Neurology , JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry .

A. Alfred Taubman Medical Research Institute

In 2007, the A. Alfred Taubman Medical Research Institute was founded to support the research of physician-scientists, with the goal of empowering medical scientists to expand the boundaries of scientific discovery, develop new medical therapies, and alleviate human suffering caused by diseases. Under Feldman’s leadership, the Taubman Institute funded senior-level physician-scientists in a broad spectrum of diseases but with special attention on adult and childhood cancer, cardiovascular and metabolic diseases, and neurological conditions such as ALS, Alzheimer’s disease and the diabetic neuropathy. The Institute’s funding focused on supporting “translational” research; the kind that transforms laboratory discoveries into treatments for patients.

She also established an Emerging Scholars program to support promising early-career physician scientists at the Taubman Institute, which has provided unencumbered seed funding to over 20 junior investigators, with an emphasis on improving the diversity of the clinician-scientist workforce.

Feldman served as Director of the Taubman Institute for 10 years. It now supports the work of over 40 of the University’s most prominent and promising clinician-scientists, almost half of which are in the Emerging Scholar Program she began.

Stem cell initiative

Feldman has been a leading spokesperson on issues related to medical science to the general community, frequently appearing in public and in the media. She has been a true ambassador for medical science. This was never more evident than the role she and the Taubman Institute played in the 2008 election when Michigan voters passed a constitutional amendment easing restrictions on embryonic stem cell research. Appearing on numerous television and radio programs, in newspaper articles and public speaking engagements, she was one of the main educators on the value of such research in the understanding and treatment of diseases. In the final days before the election, Dr. Feldman spoke alongside former President Bill Clinton at a large educational rally.

In the following year, Feldman announced the formation of the Consortium of Stem Cell Therapies at the Taubman Institute, the first facility to produce embryonic stem cell lines in Michigan and one of only a handful in the nation.

Center for RNA Biomedicine at the University of Michigan

In the fall of 2015, under the leadership of Feldman, the Taubman Institute collaborated in the creation of the now-established Center for RNA Biomedicine at the University of Michigan. It promotes and develops promotes and develops cross-disciplinary collaborations on RNA research across campus.

NeuroNetwork for Emerging Therapies

Feldman’s scientific (basic science) laboratory was initially established in 1988 and was later named the Program for Neurology Research and Discovery. In the proceeding 20 years, her lab grew to over 30 scientists and was renamed The NeuroNetwork for Emerging Therapies (www.mneuronet.org) in 2020. The mission of Feldman's research remains the same: to advance scientific discovery and establish therapies for neurological diseases.

ALS Center of Excellence at Michigan Medicine

After initially taking over the ALS Clinic at Michigan Medicine, now the Pranger ALS Clinic, Feldman combined ALS patient care and ALS clinical and scientific research.  The newly formed ALS Center of Excellence at Michigan Medicine was certified by the ALS Association. Patient care and clinical trials happen through Pranger ALS Clinic, while basic science research is conducted through the NeuroNetwork.  All ALS-related activities at the separate entities are merged under the ALS Center of Excellence to build a true bench to bedside framework, now directed by Feldman, with Dr. Stephen Goutman, Director of the Pranger ALS Clinic, serving as the associate director.

Research

Amyotrophic Lateral Schlerosis (ALS)

Feldman is renowned for her groundbreaking research in amyotrophic lateral sclerosis (ALS), an invariably fatal nerve affliction more commonly known as Lou Gehrig’s disease. In fact, her work developing a stem cell therapy for ALS has resulted in the first FDA-approved human clinical trial for a stem cell treatment for this condition. The Phase 1 and 2 trials supported the safety and feasibility of transplanting up to 16 million stem cells into the spinal cord of ALS subjects.  This is just one of the many influential advances that have emanated from her laboratory.

She has made national headlines for work uncovering links between ALS risk and pesticide exposures, and she and her team received a method-of-use patent in 2018 to repurpose a family of drugs, the Jakinibs, for use in ALS treatment based on her data identifying a novel mechanism by which the immune system contributes to disease progression. In October 2021, she received the NIH Director’s Transformative Award as the leader of an interdisciplinary team from Michigan Medicine and the School of Public Health that employs novel approaches to “omics” clinical data with the goal of making ALS a preventable disease.

Feldman also founded the University of Michigan ALS Consortium, establishing a biorepository for ALS, which has facilitated identification of epigenetic, transcriptomic, metabolomic, and immunological unique signatures in ALS along with potential biomarkers. Her work has also identified new ALS therapeutic targets, as well as environmental toxins that are potentially risk factors for the disease.

Neuropathy and diabetes complications

Feldman is equally known internationally for her work in diabetes complications, particularly peripheral neuropathy.  She received the Juvenile Diabetes Research Foundation Mary Jane Kugel Award twice (2003 and 2005), the American Diabetes Association Lifetime Achievement Award (2006), Endocrine Society Gerald D. Aurbach Award for Outstanding Translational Research (2017), and the Peripheral Nerve Society Alan J. Gebhart Prize for Excellence in Peripheral Nerve Research (2019).

Her efforts over the past 30 years in this area have changed practice guidelines for diagnosing early prediabetic neuropathy. Her early work developing the Michigan Neuropathy Screening Instrument (MNSI) has led to the tool’s widespread global use to diagnose neuropathy. She has uncovered important roles for lipids and the metabolic syndrome in neuropathy pathogenesis in prediabetes and type 2 diabetes and is an author on the American Diabetes Association Guidelines on the treatment of diabetic neuropathy. She is currently developing risk assessment tools to inform the care of COVID-19 patients with type 2 diabetes during this health crisis as well as pandemics to come, while also studying the neurological implications of patients with Long COVID.

Brain health and Alzheimer’s disease

Feldman is leading efforts to understand how metabolic dysfunction drives neurologic complications and impacts brain health. Her team found a correlation between diabetes and Alzheimer’s disease, and she has initiated a landmark study to understand how diabetes and obesity contribute to dementia. Feldman’s lab is also exploring the effects of good versus. bad fats on memory, as well as how gut health affects nerve function in both the brain and peripheral nerves.

Using the knowledge gained from her ALS stem-cell research, Feldman is developing a similar stem-cell therapy for Alzheimer’s disease, which, if approved, would be the first in-human clinical trial of its kind in medical history.

Sources

Related Research Articles

<span class="mw-page-title-main">National Institute of Neurological Disorders and Stroke</span> Department of the U.S. National Institutes of Health

The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the U.S. National Institutes of Health (NIH). It conducts and funds research on brain and nervous system disorders and has a budget of just over US$2.03 billion. The mission of NINDS is "to reduce the burden of neurological disease—a burden borne by every age group, every segment of society, and people all over the world". NINDS has established two major branches for research: an extramural branch that funds studies outside the NIH, and an intramural branch that funds research inside the NIH. Most of NINDS' budget goes to fund extramural research. NINDS' basic science research focuses on studies of the fundamental biology of the brain and nervous system, genetics, neurodegeneration, learning and memory, motor control, brain repair, and synapses. NINDS also funds clinical research related to diseases and disorders of the brain and nervous system, e.g. AIDS, Alzheimer's disease, epilepsy, muscular dystrophy, multiple sclerosis, Parkinson's disease, spinal cord injury, stroke, and traumatic brain injury.

Diabetic neuropathy is various types of nerve damage associated with diabetes mellitus. Symptoms depend on the site of nerve damage and can include motor changes such as weakness; sensory symptoms such as numbness, tingling, or pain; or autonomic changes such as urinary symptoms. These changes are thought to result from a microvascular injury involving small blood vessels that supply nerves. Relatively common conditions which may be associated with diabetic neuropathy include distal symmetric polyneuropathy; third, fourth, or sixth cranial nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; and autonomic neuropathy.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).

<span class="mw-page-title-main">Peripheral neuropathy</span> Nervous system disease affecting nerves beyond the brain and spinal cord

Peripheral neuropathy, often shortened to neuropathy, is a general term describing damage or disease affecting the nerves. Damage to nerves may impair sensation, movement, gland function, and/or organ function depending on which nerves are affected. Neuropathy affecting motor, sensory, or autonomic nerves result in different symptoms. More than one type of nerve may be affected simultaneously. Peripheral neuropathy may be acute or chronic, and may be reversible or permanent.

<span class="mw-page-title-main">Polyneuropathy</span> Medical condition

Polyneuropathy is damage or disease affecting peripheral nerves in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain. It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of Guillain–Barré syndrome.

<span class="mw-page-title-main">Leonard M. Miller School of Medicine</span> Medical school of the University of Miami

Leonard M. Miller School of Medicine (UMMSM) is the University of Miami's graduate medical school in Miami, Florida. Founded in 1952, it is the oldest medical school in the state of Florida.

The Kolling Institute is located in the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.

<span class="mw-page-title-main">Gregory Petsko</span> American biochemist and academic

Gregory A. Petsko is an American biochemist and member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society. He is currently Professor of Neurology at the Ann Romney Center for Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital. He formerly had an endowed professorship in Neurology and Neuroscience at Weill Cornell Medical College and is still an adjunct professor of Biomedical Engineering at Cornell University, and is also the Gyula and Katica Tauber Professor, Emeritus, in biochemistry and chemistry at Brandeis University. On October 24, 2023, in a ceremony in the East Room of the White House, President Joe Biden presented Gregory Petsko and eight others with the National Medal of Science, the highest honor the United States can bestow on a scientist and engineer.

Orla Hardiman is an Irish consultant neurologist. She was appointed Professor of Neurology by Trinity College University of Dublin in 2014, where she heads the Academic Unit of Neurology, housed in Trinity Biomedical Sciences Institute. She is a HRB Clinician Scientist and Consultant Neurologist at the National Neuroscience Center of Ireland at Beaumont Hospital, Dublin. She leads a team of thirty researchers focusing on clinical and translational aspects of amyotrophic lateral sclerosis and related neurodegenerations. Hardiman has become a prominent advocate for neurological patients in Ireland, and for patients within the Irish health system generally. She is co-founder of the Neurological Alliance of Ireland and Doctors Alliance for Better Public Healthcare. In the past, she established the bi-annual Diaspora Meeting, a forum for Irish neurologists based overseas to present and discuss their research findings with neurologists working in Ireland.

Peter Henry St George-Hyslop, OC, FRS, FRSC, FRCPC, is a British and Canadian medical scientist, neurologist and molecular geneticist who is known for his research into neurodegenerative diseases. St George-Hyslop is one of the most cited authors in the field of Alzheimer's disease research. He has identified a number of key genes that are responsible for nerve cell degeneration and early-onset forms of Alzheimer's disease. These include the discovery of the presenilins, Nicastrin, and SORL1 genes. Presenilin mutations are the most common cause of familial Alzheimer's disease. St George-Hyslop also co-led the discovery of the gene for the amyloid precursor protein.

<span class="mw-page-title-main">Gladstone Institutes</span>

Gladstone Institutes is an independent, non-profit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators, 2012 Nobel Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration.

Clifford J. Woolf is professor of neurology and neurobiology at Harvard Medical School and director of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital. He has added greatly to the understanding of pain.

<span class="mw-page-title-main">Jan Nolta</span> American scientist

Jan A. Nolta is an American scientist and the director of the stem cell program at the UC Davis School of Medicine and Institute for Regenerative Cures. She is Scientific Director for the UC Davis Good Manufacturing Practice and editor of the journal Stem Cells. Nolta is known for her work with stem cell-related regenerative medicine. Nolta's current research focuses on treatment of Huntington's disease using mesenchymal stem cells. She was elected a AAAS Fellow in 2013.

<span class="mw-page-title-main">Griffin P. Rodgers</span> American hematologist

Griffin P. Rodgers is the director of the National Institute of Diabetes and Digestive and Kidney Diseases, one of the 27 institutes that make up the United States National Institutes of Health. He is also the Chief of the institute's Molecular and Clinical Hematology Branch and is known for contributions to research and therapy for sickle cell anemia.

<span class="mw-page-title-main">Howard L. Weiner</span> American neurologist, neuroscientist and immunologist

Howard L. Weiner is an American neurologist, neuroscientist and immunologist who is also a writer and filmmaker. He performs clinical and basic research focused on multiple sclerosis (MS) and other neurologic diseases such as Alzheimer's disease and Lou Gehrig's disease (ALS). His work also focuses on autoimmune diseases such as diabetes. Weiner is the Robert L. Kroc Professor of Neurology at Harvard Medical School, director of the Brigham MS Center at the Brigham and Women's Hospital and co-director of the Ann Romney Center for Neurologic Diseases established in 2014, at the Brigham and Women's Hospital in Boston, Massachusetts.

<span class="mw-page-title-main">Rajiv Ratan</span> American physician

Rajiv Ratan is an Indian American academic, professor, administrator and scientist based in New York. He is the Burke Professor of Neurology and Neuroscience at Weill Cornell Medicine. Since 2003, he has served as the executive director of Burke Neurological Institute and as a member of the Council of Affiliated Deans of Weill Cornell Medicine.

<span class="mw-page-title-main">Giulio Maria Pasinetti</span>

Giulio Maria Pasinetti is the Program Director of the Center on Molecular Integrative Neuroresilience and is the Saunders Family Chair in Neurology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Pasinetti is a Professor of Neurology, Psychiatry, Neuroscience, and Geriatrics and Palliative Medicine at ISMMS.

Peripheral mononeuropathy is a nerve related disease where a single nerve, that is used to transport messages from the brain to the peripheral body, is diseased or damaged. Peripheral neuropathy is a general term that indicates any disorder of the peripheral nervous system. The name of the disorder itself can be broken down in order to understand this better; peripheral: in regard to peripheral neuropathy, refers to outside of the brain and spinal cord; neuro: means nerve related; -pathy; means disease. Peripheral mononeuropathy is a disorder that links to Peripheral Neuropathy, as it only effects a single peripheral nerve rather than several damaged or diseased nerves throughout the body. Healthy peripheral nerves are able to “carry messages from the brain and spinal cord to muscles, organs, and other body tissues”.

Kristin K. Baldwin is an American scientist who is a professor at the Department of Genetics and Development at Columbia University. Her research focuses on using reprogrammed and induced pluripotent stem cells to identify mechanisms and therapies related to human genetic risk for neurologic and cardiovascular disease. Her lab also studies how disease and aging affect the genome; they have used cloning to produce the first complete genome sequence of a single neuron and helped assess the effect of aging on induced pluripotent stem cells that may be used for cell therapies. They also design bespoke neuronal cells in a dish to understand brain function and disease. Baldwin's earlier work included being the first to clone a mouse from a neuron and being one of three groups to first produce an entire mouse from a skin cell by generating induced pluripotent stem cells. epigenetic changes of the genome and the brain.

Catarina Resende de Oliveira is a Portuguese neurologist, researcher, university professor, and doctor. A full professor of biochemistry at the Faculty of Medicine of the University of Coimbra, she studies the processes that cause neurological degeneration responsible for illnesses such as Alzheimer's disease and Parkinson's disease.

References

    See also